Global Nonalcoholic Steatohepatitis Treatment (Phase III Drugs) Market USD 19.8 Billion by 2025 - iHealthcareAnalyst, Inc.
Maryland Heights, MO, December 01, 2016 --(PR.com)-- The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market is estimated to reach USD 19.5 Billion in 2025, expanding at a CAGR of 10.0% from 2016 to 2025, published by iHealthcareAnalyst, Inc.
Visit the Nonalcoholic Steatohepatitis Treatment Market – Phase III Drugs In Pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) 2016-2025 report at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Nonalcoholic fatty liver disease (NAFLD) gradually is recognized as a common reason of chronic liver disease. NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. The diagnosis methods include evaluation of liver enzymes, hepatic imaging and liver biopsy.
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor).
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market report also provides the detailed market landscape, market drivers, restraints, opportunities, market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, and Zydus Cadila.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Visit the Nonalcoholic Steatohepatitis Treatment Market – Phase III Drugs In Pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) 2016-2025 report at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Nonalcoholic fatty liver disease (NAFLD) gradually is recognized as a common reason of chronic liver disease. NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. The diagnosis methods include evaluation of liver enzymes, hepatic imaging and liver biopsy.
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor).
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market report also provides the detailed market landscape, market drivers, restraints, opportunities, market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, and Zydus Cadila.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 736-9294
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 736-9294
https://www.ihealthcareanalyst.com/
Contact
Categories